The case concerns an abuse of dominance investigation by the CMA into the supply of Liothyronine tablets in the UK by Advanz Pharma (Advanz), previously Concordia. Because some of the arguments in the CMA’s statement of objections (issued in November 2017) depend on the ongoing cases Flynn Pharma and Pfizer, Advanz asked the CMA to delay its own case pending final outcomes in those cases. The CMA declined, arguing that its conclusions would be the same regardless of the outcome in those cases. On 5 March 2019, Advanz filed a judicial review claim challenging the CMA’s refusal to delay, which was refused by the High Court on 13 June 2019.